10x Genomics Statistics Share Statistics 10x Genomics has 124.49M
shares outstanding. The number of shares has increased by 3.62%
in one year.
Shares Outstanding 124.49M Shares Change (YoY) 3.62% Shares Change (QoQ) 2.08% Owned by Institutions (%) 92.01% Shares Floating 110.42M Failed to Deliver (FTD) Shares 109 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 13.64M, so 10.96% of the outstanding
shares have been sold short.
Short Interest 13.64M Short % of Shares Out 10.96% Short % of Float 17.59% Short Ratio (days to cover) 3.74
Valuation Ratios The PE ratio is -9.47 and the forward
PE ratio is -14.28.
10x Genomics's PEG ratio is
0.31.
PE Ratio -9.47 Forward PE -14.28 PS Ratio 2.83 Forward PS 2.9 PB Ratio 2.44 P/FCF Ratio -301.92 PEG Ratio 0.31
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for 10x Genomics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.97,
with a Debt / Equity ratio of 0.12.
Current Ratio 4.97 Quick Ratio 4.26 Debt / Equity 0.12 Debt / EBITDA -0.62 Debt / FCF -14.42 Interest Coverage -48639.75
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $467.68K Profits Per Employee $-139.84K Employee Count 1,306 Asset Turnover 0.66 Inventory Turnover 2.36
Taxes Income Tax 4.93M Effective Tax Rate -2.77%
Stock Price Statistics The stock price has increased by -35.19% in the
last 52 weeks. The beta is 2, so 10x Genomics's
price volatility has been higher than the market average.
Beta 2 52-Week Price Change -35.19% 50-Day Moving Average 13.08 200-Day Moving Average 11.99 Relative Strength Index (RSI) 56.43 Average Volume (20 Days) 3,517,496
Income Statement In the last 12 months, 10x Genomics had revenue of 610.78M
and earned -182.63M
in profits. Earnings per share was -1.52.
Revenue 610.78M Gross Profit 414.48M Operating Income -194.56M Net Income -182.63M EBITDA -133.99M EBIT -177.7M Earnings Per Share (EPS) -1.52
Full Income Statement Balance Sheet The company has 344.07M in cash and 82.61M in
debt, giving a net cash position of 261.45M.
Cash & Cash Equivalents 344.07M Total Debt 82.61M Net Cash 261.45M Retained Earnings -1.47B Total Assets 979.97M Working Capital 543.44M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 6.66M
and capital expenditures -12.39M, giving a free cash flow of -5.73M.
Operating Cash Flow 6.66M Capital Expenditures -12.39M Free Cash Flow -5.73M FCF Per Share -0.05
Full Cash Flow Statement Margins Gross margin is 67.86%, with operating and profit margins of -31.85% and -29.9%.
Gross Margin 67.86% Operating Margin -31.85% Pretax Margin -29.09% Profit Margin -29.9% EBITDA Margin -21.94% EBIT Margin -31.85% FCF Margin -0.94%
Dividends & Yields TXG does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for TXG is $14.5,
which is 3.9% higher than the current price. The consensus rating is "Buy".
Price Target $14.5 Price Target Difference 3.9% Analyst Consensus Buy Analyst Count 11
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 17, 2006. It was a
backward
split with a ratio of 1:2.
Last Split Date Jul 17, 2006 Split Type backward Split Ratio 1:2
Scores Altman Z-Score 3.74 Piotroski F-Score 5
